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Abstract: Necrotizing soft tissue infections (NSTIs) are critical clinical conditions characterized by
extensive necrosis of any layer of the soft tissue and systemic toxicity. Group A streptococci (GAS) and
Staphylococcus aureus are two major pathogens associated with monomicrobial NSTIs. In the tissue
environment, both Gram-positive bacteria secrete a variety of molecules, including pore-forming
exotoxins, superantigens, and proteases with cytolytic and immunomodulatory functions. The present
review summarizes the current knowledge about streptococcal and staphylococcal toxins in NSTIs
with a special focus on their contribution to disease progression, tissue pathology, and immune
evasion strategies.
Keywords: Streptococcus pyogenes; group A streptococcus; Staphylococcus aureus; skin infections;
necrotizing soft tissue infections; pore-forming toxins; superantigens; immunomodulatory proteases;
immune responses
Key Contribution: Group A streptococcal and Staphylococcus aureus toxins manipulate host
physiological and immunological responses to promote disease severity and progression.
1. Introduction
Necrotizing soft tissue infections (NSTIs) are rare and represent a more severe rapidly progressing
form of soft tissue infections that account for significant morbidity and mortality [1]. NSTIs can be
classified according to the invading organisms (types I–III), and less commonly, the depth of invasion,
or anatomic location (trunk, extremity, perineum) [1–4]. Type I NSTIs, also referred to as synergistic
NSTIs, affect around 70%–80% of patients seen in practice [1,3]. They are of a polymicrobial nature,
frequently involving a mixture of aerobic and anaerobic bacteria [5] and affect elderly and/or patients
with multiple underlying conditions, including diabetes mellitus, obesity, vascular diseases, renal
insufficiency, and immunosuppression [6]. Type II NSTIs, causing around 20%–30% of cases, are of a
monomicrobial nature mostly due to Gram-positive organisms. Among these, Streptococcus pyogenes
(group A streptococcus [GAS]) is the most common pathogen [7–10]. Although S. aureus has not
been described as a monomicrobial cause of NSTIs in clinical settings until 2005, the number of
methicillin-resistant S. aureus (MRSA) NSTIs is constantly increasing leading to the second major
species responsible for type II NSTIs [11]. Type II NSTIs affect mostly young individuals without
underlying conditions with a recent history of trauma to an extremity or intravenous drug abuse [4].
Type III infections are confined to warm coastal areas and are caused mainly by Gram-negative Vibrio
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species [1,12]. This review article focuses solely on type II NSTIs caused by GAS and S. aureus and the
role of respective exotoxins and secreted proteases contributing to the severity of infection.
2. Pathophysiology of Type II NSTIs
GAS and S. aureus are Gram-positive cocci, which share many features, including clinical
aspects and pathogenic mechanisms. Both secrete virulence factors with pore-forming and/or
immunomodulatory properties (Figure 1). However, they also have unique features. S. aureus
is a major cause of community- and hospital-acquired infections ranging from mild superficial skin
and throat infections to invasive infections such as toxic shock syndrome (TSS) and NSTIs [13]. A great
public health concern is the increasing prevalence of MRSA, specifically the rise in community-acquired
(CA) S. aureus [13–15]. Specifically CA-MRSA clones are associated with highly aggressive infections,
including NSTIs, in otherwise healthy individuals [11]. GAS with an estimate of 500,000 deaths
annually is rated as number nine on the list of global killer pathogens [16]. GAS can cause a variety of
diseases in immunocompetent individuals similar to those listed for S. aureus [16].
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Figure 1. Streptococcal and staphylococcal secreted virulence factors with pore-forming and/or 
immunomodulatory properties. (a) Group A streptococcal (GAS) secreted factors: Streptolysins S and 
O (SLS, SLO), streptococcal pyrogenic exotoxin B (SpeB), superantigens (SAgs), C5a peptidase (ScpA), 
Immunoglobulin degrading enzyme of streptococci (IdeS), SpyCEP, SpyA, Streptokinase (Ska), and 
NADase. (b) Staphylococcal secreted factors: Leukocidins, α-toxin, phenol-soluble modulins (PSMs), 
superantigens (SAgs), staphopain A (ScpA), Staphopain B (SspB), Aureolysin (Aur), V8 protease, 
exfoliative toxins (ETs), epidermin leader processing protease (EpiP), serine protease-like proteins 
(Spls), and staphylokinase (SAK). 
Type II NSTIs can present with or without a defined portal of entry [4]. In ca. 50% of cases the 
Gram-positive cocci can gain entry to the deeper tissue (i) after breaches of the skin due to drug 
injections, incisions or childbirth, (ii) through superficial lesions (e.g., lacerations or insect bites), or 
(iii) after a penetrating trauma [1]. The proliferation of the bacteria leads to the release of exotoxins, 
which will cause tissue damage and impair the initial and very crucial inflammatory response. Within 
the next 24–72 h toxin induced local coagulation disturbances and damage of the endothelium lead 
to fluid leakage, tissue swelling, and erythema. These changes become widespread leading to the 
development of bullae, ecchymoses, and further bacterial spread to the deeper layers of the tissue. 
Further exotoxin production by bacteria leads to occlusion of major vessels with subsequent necrosis 
of all tissue layers including muscles [4,17]. In the other 50% of cases, NSTIs initiate without a portal 
of entry, often at sites of non-penetrating trauma (e.g., blunt trauma and bruises) [18]. Tissue injury 
initiates an influx of leukocytes, activation of myogenic progenitor cells, and trafficking of the 
microorganisms, by a yet unknown mechanism of initiation, to the affected site [4]. Again, bacteria 
start to proliferate and produce exotoxins, which leads to the occlusion of arteries. Subsequently, 
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im unomodulatory properties. (a) Group A strept occal (GAS) secreted facto s: Streptolysins S
and O ( L , SLO), streptococcal pyrogenic exotoxin (SpeB), superantigens (SAgs), C5a peptidase
(ScpA), Immunoglobulin egrading enzyme of streptococci (IdeS), SpyCEP pyA, Streptokin se (Ska),
and NADase. (b) Staphylococcal s creted factors: Leukocidins, α-toxin, phenol-sol ble modulins
(PSMs), superantigens (SAgs), staphopain A (ScpA), Staphopain B (SspB), Aureolysin (Aur), V8
protease, exfoliative toxins (ETs), epidermin leader processing protease (EpiP), serine protease-like
proteins (Spls), and staphylokinase (SAK).
Type II NSTIs can present with or without a efi e ortal of entry [4]. In ca. 50% of cases the
Gram-positive cocci can gain entry to the deeper tissue (i) after breaches of the skin due to drug injections,
incisions or childbirth, (ii) through superficial lesions (e.g., lacerations or insect bites), or (iii) after a
penetrating trauma [1]. The proliferation of the bacteria leads to the release of exotoxins, which will
cause tissue damage and impair the initial and very crucial inflammatory response. Within the next
24–72 h toxin induced local coagulation disturbances and damage of the endothelium lead to fluid
leakage, tissue swelling, and erythema. These changes become widespread leading to the development
of bullae, ecchymoses, and further bacterial spread to the deeper layers of the tissue. Further exotoxin
production by bacteria leads to occlusion of major vessels with subsequent necrosis of all tissue layers
including muscles [4,17]. In the other 50% of cases, NSTIs initiate without a portal of entry, often
at sites of non-penetrating trauma (e.g., blunt trauma and bruises) [18]. Tissue injury initiates an
influx of leukocytes, activation of myogenic progenitor cells, and trafficking of the microorganisms,
by a yet unknown mechanism of initiation, to the affected site [4]. Again, bacteria start to proliferate
and produce exotoxins, which leads to the occlusion of arteries. Subsequently, these events result in
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necrosis of the deeper tissue that spreads to upper tissue layers. In contrast to NSTIs with a defined
portal of entry, the bullae and ecchymoses develop later [4].
3. Superantigens and Toxic Shock Syndrome
Invasive GAS infections are often complicated by streptococcal toxic shock syndrome (STSS) [19].
According to Sepsis-3 consensus, sepsis is a life-threatening organ dysfunction caused by a dysregulated
host response to infection. Toxic shock is a subset of sepsis in which particularly profound circulatory,
cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis
alone [20]. Approximately 50% of GAS NSTI cases are associated with STSS [21,22], which significantly
increases the mortality of GAS NSTIs [21,23]. Although less common, staphylococcal TSS was also
reported in cases of skin and soft tissue infections [24]. Staphylococcal TSS is divided in two categories,
menstrual and non-menstrual [25]. Menstrual TSS occurs within two days of a woman´s menstrual
period and is usually associated with tampon use. Approximately half of the reported cases are of
a non-menstrual nature and are reported in a variety of cases, including surgical wound infections,
burns, and cutaneous and subcutaneous lesions. The fatality rate of these infections remains around
5% [26].
Toxic shock presents classically in three phases. The first phase is characterized by fever, myalgia,
headache, and chills. Nausea, vomiting, and diarrhea may also be present. The second phase expands to
systemic manifestations, such as tachycardia, tachypnea, and high fever. In STSS, pain is present in the
affected limb, abdomen or thorax. The third phase is characterized by circulatory shock accompanied
by multi-organ failure [27]. Both, STSS and staphylococcal TSS are superantigen-driven diseases.
However, STSS is a result of an invasive infection (e.g., NSTI), while staphylococcal TSS is secondary to
a localized infection (e.g., infections of postsurgical or postpartum injuries, burns, soft tissue injuries,
and focal infections) [28]. Superantigens (SAgs) are recognized as key exotoxins mediating the systemic
excessive inflammatory response of the host [29]. To date, 26 staphylococcal and 11 streptococcal SAgs
were identified [30,31]. S. aureus SAgs include the toxic shock syndrome toxin 1 (TSST-1), staphylococcal
enterotoxins (SEs) A-E and G-I, and SE-like (SEl) SAgs J-Z [31,32]. The SEs are defined by their emetic
activity, while SEls lack this activity or have not been tested yet [32]. TSST-1 was among the first SAgs
to be associated with staphylococcal TSS [33]. Streptococcal SAgs include streptococcal pyrogenic
exotoxins (Spe) A, C, G-M, streptococcal superantigen (SSA), and streptococcal mitogenic exotoxin Z
(SmeZ) [30].
For many years, SAgs were known as pyrogenic toxins based on their common pyrogenic
activity [34]. Marrack and Kappler suggested the term superantigen, to emphasize the stimulatory
capacity of these exotoxins on T cells [35]. SAgs bind without prior cellular processing to α- and/or
β-chains of the major histocompatibility complex (MHC) class II molecules on antigen-presenting
cells (APCs) and to the variable β-chains on the T-cell receptor (TCR; Figure 2) [36]. In addition,
SAgs can also bind a co-stimulatory molecule CD28 and its ligand CD86 (B7-2) [37,38]. Once the fine
MHC-peptide specificity of T cells is bypassed, these interactions result in a massive cytokine storm,
including tumor necrosis factor (TNF), interferon (IFN)-γ, interleukin (IL)-1, IL-2, IL-6, CXCL8, CCL2,
and CCL3 [39].
The majority of the SAg studies are confined to systemic effects and only a limited number of
studies investigated SAg-driven events at the deep tissue site [19,40]. A recent study showed that
staphylococcal SAgs TSST-1, SEB, and SEC facilitate the attraction of the adaptive immune system to
the local environment through their binding to CD40 on human vaginal epithelial cells [41]. The data
suggest that, especially in cases of menstrual TSS, SAgs facilitate infections by the disruption of
mucosal barriers and subsequently stimulates chemokine production [41]. Thus, the data indicate that
SAg-driven activation of T cells may induce the abundance of homing receptors and thereby promote
the migration of activated T cells to the skin or mucosal surfaces. Subsequently, these events lead to
exacerbated inflammation of the infected tissue.
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studies have demonstrated that SLS is a crucial virulence factor in GAS NSTIs [45]. SLS-negative 
mutants were less virulent in a mouse skin infection model as compared to parental wildtype strains 
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guaranteed via the induction of pyroptosis [53]. An out-of-proportion pain is a critical feature of 
Figure 2. Superantigen (SAg) driven T cell activation. (a) Antigen presenting cell (APC) presents a
processed antigen peptide on the MHC class II molecule to a T cell via T cell receptor. A process called
conventional antigen presentation. (b) SAgs bind without cellular processing to MHC class II molecule
and variable beta (Vβ) chain on the T cell receptor. This results in uncontrolled T cell activation.
4. Pore-Forming Toxins
Pore-forming t i s are a class of bacterial virulence factors that disrupt eukaryotic membrane
barriers, cause cell lysis, and have immuno-modulatory functions. In this section, we discuss major
GAS and staphylococcal pore-forming toxins and their potential implications in NSTIs.
4.1. GAS Pore-Forming Toxins
Nearly all clinical GAS isolates secrete a potent hemolysin streptolysin S (SLS) [42]. SLS is
a small (2.7 kDa) peptide with the ability to lyse red blood cells, which is typically visualized as
a zone of clearance around GAS colonies on blood agar plates, a process called β-hemolysis [43].
SLS is encoded by the SLS-associated gene (sag) locus consisting of nine genes (sagABCDEFGHI) [44].
The sagA gene encodes the premature form of SLS, while the others are required for post-translational
modification, processing, and export of the ma ure SLS [44,45]. SLS is cy olytic only when associated
with the bacterial cell surface or carrier molecules [46] and it targets primarily red blood cells, platelets,
subcellular organelles, and leukocyt s [47– 9 . It has been uggested that SLS ac umulates in cell
membranes of eukaryotic cells leading to pore formation a d irreversible osmotic lysis of the cells [50],
but the exact mechanism is not yet fully understood. A recent study by Higashi and colleagues showed
that red blood cell hemolysis by GAS is caused by interactions of SLS with the major erythrocyte anion
exchange protein band 3 leading to an osmotic change characterized by a rapid influx of Cl− ions [43].
This finding led the authors to hypothesize that SLS might disrupt similar anion channels in other cell
types such as leukocytes, keratinocytes, and endothelial cells [43]. In vivo studies have demonstrated
that SLS is a crucial virulence factor in GAS NSTIs [45]. SLS-negative mutants were less virulent
in a mouse skin infection model as compared to parental wildtype strains [51], suggesting that SLS
expression is detrimental for the pathogenesis of destructive infections. SLS facilitates the translocation
of GAS across the epithelial barrier through direct cleavage of junctional proteins occludin and
E-cadherin (Figure 3) [52]. In addition, direct damage to keratinocytes is guaranteed via the induction
of pyroptosis [53]. An out-of-proportion pain is a critical feature of NSTIs at early stage of infection [1].
A recent study has discovered that SLS activates sensory neurons to produce pain [54]. This leads to a
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release of neuropeptides that suppress the recruitment of neutrophils to the site of infection and allows
the bacteria to spread [54]. Once deeper layers are reached, the direct cytotoxicity of SLS towards
a variety of cells residing within the skin tissue and feeding vessels provokes neutrophil influx and
further contributes to tissue damage by synergizing with neutrophil-derived factors [55]. Moreover,
SLS actively destroys neutrophils which are recruited to the site of infection [56]. This contributes to a
negative outcome in patients in two ways; (i) reduced numbers or lack of neutrophils in the infected
tissue is an unfavorable prognostic sign in GAS NSTIs [57] and (ii) neutrophil derived effector molecules
contribute to hyper-inflammation and tissue damage [19,58,59]. It has also been suggested that SLS
impairs the phagocytic clearance of bacteria and further synergizes with other streptococcal virulence
factors, such as Streptolysin O (SLO) and the M-protein to augment tissue injury [60]. Failed clearance
of the pathogen in deeper tissue layers allows the bacteria to spread and become systemic. In addition,
the bacteria can form biofilm, a recently discovered finding in patients suffering from GAS NSTIs [61].
In line with this discovery, Vajjala and colleagues have shown that both streptolysins (SLS and SLO)
are required for inducing endoplasmic reticulum stress in the host which, in turn, promotes GAS
invasiveness into deeper tissue and biofilm formation [62].Toxins 2019, 11, x FOR PEER REVIEW 6 of 28 
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SLO is a 57 kDa oxygen-sensitive, cholesterol-dependent cytolysin, which is encoded by the highly
conserved slo gene [63]. SLO targets several eukaryotic cells, including macrophages, neutrophils,
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epithelial cells, and endothelial cells [63]. It disrupts cytoplasmic membrane integrity through pore
formation, thereby inducing cell death through pyroptosis [64], apoptosis [65], and necrosis [66].
Despite its cytolytic activity, SLO is able to suppress crucial neutrophil functions at early stages of
infection, including migration, oxidative burst, degranulation, release of other pro-inflammatory
mediators, and formation of neutrophil extracellular traps (NET) [67]. In addition, SLO contributes
to impaired phagocytic clearance of GAS, thereby enhancing bacterial virulence in murine infection
models [68]. Zhu and colleagues have shown that a GAS mutant lacking slo gene was significantly
attenuated in a murine soft tissue infection model [69]. SLO expression is regulated by the
two-component system CovR/S, which is known to regulate the expression of up to 15% of the
GAS genome [70]. Tissue passage of GAS selects for covR/S mutations resulting in an upregulated
SLO expression and further systemic dissemination of the bacteria [71,72]. In addition, Sumby and
colleagues have shown that a frameshift mutation in the covS gene results in an up-regulation of slo
transcripts [73]. Furthermore, strains with a non-functional CovR/S TCS were characterized by a
higher secretion of SLO, suggesting that CovR/S acts as a repressor of several virulence relevant genes
including slo [73]. In line with this, it was demonstrated that bacterial isolates derived from invasive
human infections show higher SLO activity as compared to isolates from non-invasive infections [74].
Also, antimicrobial peptide LL-37, which is highly abundant in necrotic tissue [75], contributes through
the CovR/S system to upregulation of SLO expression and promotes resistance of GAS to killing
by human epithelial cells, neutrophils, and macrophages [76]. Moreover, LL-37 promotes vesicle
formation by GAS, which contain SLO among other virulence factors, further contributing to GAS
pathogenesis [77].
4.2. Staphylococcal Pore-Forming Toxins
Alpha toxin (also referred as Hla or Hemolysin-α) is a 33.3 kDa water soluble monomer and is
secreted by approximately 95% of S. aureus isolates [78]. NSTI-associated CA-MRSA strains tend to
express higher levels of this protein as compared to hospital-acquired (HA) MRSA strains [79,80].
Alpha toxin lyses human platelets, endothelial cells, epithelial cells, keratinocytes and leukocytes in
two different ways [81]. First, high amounts of the secreted monomeric components integrate via
the binding of phosphatidylcholine or sphingomyelin and cholesterol into the membrane of target
cells [82,83]. The resultant heptamer structure subsequently leads to the pore formation and lysis of
the cells [84]. Second, at lower concentrations, alpha toxin binds A Disintegrin and Matalloprotease 10
(ADAM10) [85] leading to the induction of catalytic activity of the receptor. ADAM10 is a eukaryotic
cell surface protease, which is expressed by keratinocytes, endothelial cells, and platelets [86–89] and
whose substrates are members of the notch, ephrin, and cadherin families [87,90–92]. The loss of the
adherence junctions of the epithelium, e.g., due to the cleavage of E-cadherin, disrupts the epithelial
barrier function [93]. Alpha toxin induced pore formation and the resulting Ca2+ influx further enhance
ADAM10 activity [92,94].
Unlike α-toxin, leukocidins consist of two components and are hetero-oligomeric.
Woodin demonstrated for the first time the bi-component composition through the fractionation
of the Panton-Valentine Leukocidin (PVL) [95]. Using ion-exchange chromatography, it was shown
that PVL consists of a subunit F and S representing fast and slow fractions, respectively [95]. This study
showed that the two subunits must be combined to reach the maximum cytolytic activity [95].
The assembled leukocidins are octamers consisting of four F and four S subunits [96]. Except of LukAB,
which either dimerizes after secretion or is released as a dimer [97,98], the S subunits bind to specific
host cell receptors and induce conformational changes to allow dimerization with F subunits, followed
by oligomerization of the dimers to form a pre-pore [99]. To date, seven bi-component leukocidins,
namely PVL, LukAB, LukED, HlgAB, HlgBC, LukMF´, and LukPQ are described in S. aureus (Table 1).
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Table 1. S. aureus leukocidin receptors and human target cells.
Leukocidin Other Names Receptors Human Cell Targets
PVL PVL-LukSV C5aR1C5aR2
Neutrophils
Monocytes
Macrophages
LukAB LukGH CD11b
Neutrophils
Monocytes
Macrophages
Dendritic cells
LukED
CCR5
CXCR1
CXCR2
DARC
T cells
Neutrophils
Monocytes
Dendritic cells
Erythrocytes
HlgAB γ-hemolysin
γ-toxin
CXCR1
CXCR2
CXCR4
CCR2
DARC
Neutrophils
Monocytes
Macrophages
Erythrocytes
HlgCB
Leukocidin
γ-hemolysin
γ-toxin
C5aR1
C5aR2
Neutrophils
Monocytes
Macrophages
In this review, we limit our discussion to only five, as LukMF´ and LukPQ are circulating in
S. aureus stains infecting non-human hosts [100,101]. Leukocidins kill human cells and/or modulate
the host cell signaling. At higher concentration, the formation of pores ultimately results in cell
death. PVL, HlgAB, HlgCB, and LukAB activate the NOD-, LRR- and pyrin domain containing 3
(NLRP3) inflammasome in monocytes and macrophages [102–105]. Following NLRP3 activation,
caspase 1 triggers a pro-inflammatory response and induces pyroptosis [102–106]. At lower toxin
concentrations, leukocidins can alter the activation of neutrophils [107,108], trigger the formation of
NETs [109], and alter the intracellular signaling in macrophages and neutrophils [102,104,106].
PVL, encoded by the genes lukF-PV and lukS-PV on bacteriophages [110], was predominantly found
(77–100%) in CA-MRSA strains [111,112], which were isolated from skin and soft tissue infections [113,
114]. In contrast, less than 3% of colonizing S. aureus strains have the PVL genes [115]. It has been
difficult to investigate the role of PVL in human infectious diseases. Due to receptor specificity, murine
models have been proven to be unreliable to study PVL functions [116]. In contrast, rabbit models have
demonstrated to be a useful tool to study diseases, such as necrotizing pneumonia [116]. However,
rabbit studies confined to the role of PVL in skin infections contradict each other. While Lipinska and
colleagues showed that PVL contributes to tissue pathology in the early stages of infection [117], others
could not detect a role of PVL in NSTIs [118]. In contrast to animal models, using a panel of monoclonal
antibodies against transmembrane proteins expressed by human neutrophils and macrophages, Spaan
and colleagues showed that the human C5a receptors 1 and 2 (C5aR1 and C5aR2) are able to bind the S
subunit of PVL and facilitate pore formation [108]. In addition, genome wide CRISPR-Cas9 screen of
U937 cells identified human CD45 as a receptor for the F subunit of PVL [119]. CD45 is expressed on
all nucleated hematopoietic cells, including T cells, B cells, and cells of the myeloid lineage [120].
LukAB is a recently discovered leukocidin. Apart from its release into surrounding tissue, it is
also present on bacterial surface [98]. The majority of S. aureus strains harbor the genes lukAB [121],
but three out of ten strains fail to express and secrete the protein [122]. The role of LukAB in infections
remains elusive. Ex vivo studies showed that LukAB kills human neutrophils by direct interaction
with the α-subunit of the αM/β2 integrin (CD11b) [123]. In addition, LukAB can synergize with PVL
resulting in cytolytic activity towards monocytes, dendritic cells, and neutrophils [98,104].
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LukED is another recently discovered leukocidin. Epidemiological studies showed that about
99% of CA-MRSA strains contain the lukED locus, whereas MSSA strains were less likely to contain the
genes (44%–77%) [115]. CCR5 was identified as a first LukED receptor by screening the susceptibility of
different human cell types, including T cells, macrophages, and dendritic cells [124]. Further analysis
identified chemokine receptors CXCR1 and CXCR2 as LukED receptors on neutrophils and monocytes,
which were not expressing CCR5 [125]. Together with HlgAB, LukED belongs to the most potent
hemolytic leukocidins against human erythrocytes [126]. Both leukocidins target Duffy antigen receptor
for chemokines (DARC) to lyse erythrocytes, which, in turn, contributes to S. aureus growth due to iron
release [126].
γ-Hemolysins (HlgAB and HlgCB) share the same F subunit HlgB, but differ in their S subunit.
Both are encoded within the same locus by three genes hlgABC [127]. Up to 99% of S. aureus strains
associated with human colonization express both hemolysins [128]. HlgAB exhibits cytolytic activity
towards human red blood cells and leukocytes [129,130], whereas HlgCB is primarily leukotoxic and
exhibits only limited cytolytic activity towards red blood cells [131]. As mentioned above, red blood
cell lysis is assured through the HlgAB and DARC interaction [126]. In addition, CXCR1, CXCR2,
CXCR4, and CCR2 were identified as HlgAB receptors on human neutrophils and macrophages [131].
In contrast, HlgCB interacts with human neutrophils and monocytes via complement receptors C5aR1
and C5aR2 [131].
Phenol-soluble modulins (PSMs) are another class of staphylococcal pore-forming toxins which
were discovered first in S. epidermidis in 1999 [132]. Eight years later, PSMs were also identified
within S. aureus core genome [133]. PSMs are divided in two different subfamilies. PSMα peptides
(PSMα1- PSMα4 and δ-hemolysin [Hld]) of short amino acid sequence (20–26) are encoded within
the psmα operon. PSMβs (PSMβ1 and PSMβ2), which are long peptides (40–44 amino acids)
are encoded within the psmβ operon [134]. δ-Hemolysin is encoded within the coding sequence
of RNAIII [135]. PSM peptides have a strong impact on the capacity of S. aureus to cause skin
infections [118,133]. Especially, CA-MRSA strains tend to express higher amounts of PSMs as
compared to HA-MRSA strains [118,133]. One of the major contributions of PSMs to S. aureus
pathogenesis is the ability to lyse eukaryotic cells. In contrast to α-toxin and bi-component leukocidins,
it is most likely a receptor independent process [136]. PSMα peptides have the strongest ability
to lyse erythrocytes and leukocytes, Hld has moderate cytolytic activity, and PSMβ peptides are
not cytolytic [137]. Several studies have demonstrated that PSMα peptides facilitate killing of
osteoblasts [138] and neutrophils after phagocytosis [139,140]. At sublytic concentrations, PSMα4
initiates pro-inflammatory responses, including chemoattraction and activation of neutrophils leading to
a release of CXCL8 [133,136] and heparin-binding protein, which further induces vascular leakage [141].
PSMα1, PSMα3, and Hld can also induce mast cell degranulation [142] and stimulate IL-10 production
by human dendritic cells, which in turn suppresses secretion of pro-inflammatory cytokines [143].
Consequently, these dendritic cells favor priming of regulatory T cells with suppressor function,
thereby impairing the Th1 response [143]. Recently, it was also shown that PSMα triggers cutaneous
inflammation [144]. The release of IL-1α and IL-36α by keratinocytes drives IL-17 production by
γδ T cells and type 3 innate lymphoid cells (ILC3) leading to neutrophil recruitment to the site of
infection [144].
Although several virulence factors are implicated in contributing towards fulminant NSTIs,
each exotoxin might play a certain redundant and/or non-redundant role in eliciting tissue damage and
inflammation. During NSTIs, several of these secreted virulence factors might be co-expressed and in
turn collectively contribute towards fulminant infections. The cell specificity of these several toxins
may play a major role in the coordinated action of the toxin-induced tissue damage. For example,
α-toxin and PVL can synergize. Alpha toxin induces the direct cytolytic effect towards epithelial cells
which will result in CXCL8 release and subsequent neutrophil chemotaxis. The presence of PVL will
activate and lyse recruited neutrophils exacerbating the tissue damage [106,145]. This phenomenon
has been mainly shown in experiments using lung epithelial cells. A similar mode of action might also
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be relevant in NSTIs. Similarly, both PVL and LukAB can individually cause neutrophil lysis, but their
cytotoxic effect is further enhanced when combined together [98,106]. In addition, SAg-translocation
(e.g., TSST-1) is augmented by α-toxin and leukocidins which further enhances inflammation of the
epithelium and contributes towards epithelial barrier disruption [146,147]. Although this coordinated
effect of toxin synergism has not been empirically tested during NSTIs, focusing only on individual
toxins can definitely obscure the co-operative actions during infection. Hence, further studies focusing
on toxin synergisms during NSTIs need to be conducted. Potentially, these combined effects on specific
cell types can amplify tissue pathology to the benefit of the invading bacteria and may define the
disease severity and clinical outcome.
5. Proteases and Other Immune-Modulatory Toxins
Proteases are secreted virulence factors which promote establishment of infection through damage
of barriers. They inhibit transmigration of immune cells to the site of infection and suppress their
function. In this section, we discuss major streptococcal and staphylococcal proteases and their
implication in NSTIs.
5.1. Streptococcal Proteases and Other Toxins
Despite its name, streptococcal pyrogenic exotoxin B (SpeB), SpeB is neither pyrogenic nor an
exotoxin. SpeB is a cysteine protease and one of the first proteases identified in GAS [148]. The speB
gene is highly conserved in all GAS strains [149]. The gene encodes a zymogen of 40 kDa that
is autocatalytically cleaved into a mature 28 kDa protein [150]. SpeB cleaves a broad spectrum of
streptococcal and human host proteins. On the bacterial site, SpeB is able (i) to remove proteins from
the surface, which includes M-protein, fibronectin-binding proteins, and C5a peptidase [151–153] and
(ii) to hydrolyze secreted proteins, such as streptokinase, EndoS, SLO, and SAgs [154–157]. On the
host site, SpeB cleaves IgG into Fc and Fab fragments and degrades IgA, IgM, IgD, and IgE [158].
The cleavage of IgG results in impaired opsonophagocytosis and increased survival of GAS in human
blood [159]. Further, SpeB cleaves components of the complement activation pathway. Kuo and
colleagues demonstrated that C3b is cleaved by SpeB leading to impaired phagocytic killing of bacteria
by neutrophils [160]. In support of this, Terrao and colleagues detected only degraded C3b fragments
in sera of patients diagnosed with STSS [161]. Moreover, SpeB degrades a wide range of chemokines,
including, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL10, CXCL11, CXCL12,
CXCL13, CXCL14, CXCL16, CCL20, XCL1, and CX3CL1 [162] and cleaves pro-IL-1β into biologically
active IL-1β [163]. It was suggested that IL-1β, which activates the NLRP3 inflammasome acts as a
sensor of intracellular proteolytic activity of SpeB [164]. Moreover, IL-1β pathway plays a key role in
modulating susceptibility of the host to GAS NSTIs [165]. SpeB also interferes with coagulation and
anticoagulation pathways by degrading fibrinogen and plasmin, respectively [166,167] and contributes
to tissue pathology via the degradation of extracellular matrix proteins and the activation of matrix
metalloproteases [168,169].
Although SpeB shows such a broad spectrum of substrates, its role in invasive GAS infections is still
controversial. The speB gene can be found in isolates from all types of diseases [170,171]. Some studies
show that SpeB is readily detectable in patients´ sera and tissues [61,172]. Others demonstrate that
SpeB amounts and activity produced by isolates from non-severe cases are higher as compared to
isolates from severe cases [173]. However, low anti-SpeB antibody titers have been associated with
severe diseases [174]. This controversy continues also in interpretation of the results generated from
mice models. While some authors report that SpeB contributes to disease severity, mortality, bacterial
dissemination, and tissue damage [175–178], others show that speB-deficient strains are as virulent as
the parental wild type strains [179,180]. Loss of SpeB expression through mutations in covR/S or ropB is
believed to trigger a hyper-virulent phenotype of bacteria [72]. However, human tissues from NSTIs
cases are strongly positive for SpeB [61,75]. As recently shown, most likely it is a mixed population of
SpeB-positive and SpeB-negative clones contributing to tissue pathology and disease severity [61].
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Immunoglobulin degrading enzyme of S. pyogenes (IdeS) is a 35 kDa secreted cysteine protease
which hydrolyses four subclasses of human IgG [181]. As a consequence, bacterial bound IgGs that are
cleaved by IdeS lack IgG-Fc receptor and complement binding/activation capability. Apart from its
implications as an important anti-phagocytic virulence factor [182], the role of IdeS in NSTIs is not
yet clear.
GAS express two major subtilisin-like serine proteases with immunomodulatory functions, C5a
peptidase (ScpA) and SpyCEP. ScpA contains an LPXTG motif which facilitates anchoring of the
protein to the bacterial cell wall [183]. Until recently, the human anaphylatoxin C5a was reported
as the only substrate for ScpA [184]. The cleavage of C5a results in impaired neutrophil activation
and recruitment to the site of infection [185]. Recently, Lynskey and colleagues identified C3 and C3a
as novel substrates for ScpA [186]. Cleavage of C3a leads to impaired human neutrophil activation,
phagocytosis, and chemotaxis, while cleavage of C3 generated C3a and C3b fragments with impaired
functions [186]. SpyCEP is a 180 kDa, surface-exposed, subtilisin-like serine protease that helps
GAS to disseminate in soft tissue [187,188]. SpyCEP is highly expressed in vivo [189] and cleaves
CXC chemokines, including CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL8 [187,188,190],
which results in an impaired chemoattraction of eosinophils, neutrophils, and monocytes to the site
of infection [189,191]. Moreover, SpyCEP promotes resistance to phagocytic clearance of bacteria by
reducing formation of NETs [189]. Recently it was also shown that functional SpyCEP is detrimental
for invasion of human epithelial and endothelial cells and for biofilm formation [192].
NAD-glycohydrolase (NADase) is encoded by the nga gene and is co-transcribed with the slo
gene [193]. NADase cleaves NAD in mammalian cells, thereby promoting cytotoxicity through the
depletion of energy sources [194]. Several in vivo and in vitro studies have demonstrated synergistic
toxicity by SLO and NADase in GAS infections [69,193]. A recent study suggests that binding of
NADase to SLO stabilizes both toxins, thereby increasing host cell toxicity [195].
SpyA is a 25 kDa surface exposed C3-like ADP-ribosyltransferase which catalyzes the transfer
of an ADP ribose moiety of NAD+ to target proteins [196–198]. It is believed that SpyA modifies
actin, vimentin, and tropomyosin to disrupt cytoskeletal structures and promote colonization of the
host [196]. In addition, SpyA induces pyroptosis in macrophages, resulting in a release of IL-1β,
which in turn enhances bacterial clearance [199].
Streptokinase (Ska) is a plasminogen activator protein which non-enzymatically converts
plasminogen to proteolytically active plasmin [200]. To date, Ska has been found in all GAS isolates.
The molecule is comprised of three domains (α, β, and γ) and three distinct ska alleles, type 1, 2a, and 2b
have been described [201]. The majority of GAS strains isolated from skin infections are harboring
type 2b ska allele [201]. Although Ska activates plasminogen, it is not a protease. GAS cover their
surface via different surface anchored or surface associated virulence factors with plasminogen, which,
in turn, leads to acquisition of streptokinase [202,203]. The Ska-plasminogen interaction leads to
exposure of an active site in the complex, which results in a proteolytical conversion of plasminogen to
plasmin [204,205]. Due to host-specificity of Ska, GAS are exclusively human pathogens, no differences
in virulence between wildtype and ska-deficient GAS mutants are seen in murine infection models [206].
In humanized transgenic mice, expressing human plasminogen, the mortality of mice infected with
ska-mutant is largely abrogated [207]. In line with this, the SpeB-negative M1T1 GAS variant 5448AP
expresses higher levels of Ska as compared to the parental strain 5448 and shows higher surface
plasminogen acquisition resulting in hyper-virulence in a subcutaneous infection model of humanized
transgenic mice [72].
5.2. Staphylococcal Proteases and Other Toxins
Staphylococcal cysteine proteases are papain-like proteases that belong to the C47 family of
cysteine peptidases. They can directly or indirectly damage the epithelium as well as connective
tissue [208]. Two cysteine proteases, staphopain A (ScpA) and staphopain B (SspB), were identified in
S. aureus. ScpA is a 20 kDa protein, which auto-activates upon release into environment [209]. Its broad
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spectrum of substrates includes collagen, elastin, fibronectin, fibrinogen, and kininogen [210,211].
In addition, ScpA blocks CXCR2 on neutrophils via cleavage of the N-terminal domain, making
neutrophils unresponsive to activation by all CXCR2 ligands [212]. Moreover, this cleavage results in
impaired neutrophil migration towards CXCR2 chemokines [212]. SspB is a 20 kDa peptidase, which is
structurally related to ScpA [209]. SspB cleaves CD11b on monocytes and neutrophils resulting in
an atypical cell death [213]. Moreover, SspB blocks phagocytosis of S. aureus by neutrophils and
monocytes and represses their chemotactic activity by a yet unknown mechanism [214].
The group of staphylococcal serine proteases encloses three major classes: the SspA (or V8
protease), epidermin leader peptide processing serine protease (EpiP), and exfoliative toxins (ETs).
V8 protease is secreted as an inactive precursor and requires aureolysin (Aur) for its maturation [209].
The mature V8 protease degrades the Fc region of immunoglobulins leading to impaired interaction of
immune effector cells with the antigen [215]. In skin infections, V8 protease disrupts the structure of the
stratum corneum but does not cause epidermal hyper-proliferation or inflammatory cell infiltration [216].
The role of EpiP in S. aureus pathogenesis is not fully understood. EpiP is a subtilisin-like serine protease
that cleaves collagen [217]. Mice vaccinated with EpiP were protected from subcutaneous S. aureus
infection [217]. As mentioned above, its structural homologue in S. pyogenes, SpyCEP, inactivates CXCL8
and impairs the recruitment of neutrophils to the site of infection [187,189]. However, whether EpiP
has similar pathogenic mechanisms remains to be investigated. The third class of serine proteases are
the epidermolytic ETs. Although not involved in severe skin infections, ETs can cause breakage of
the upper layers of the skin [218]. Four ETs, namely ETA, ETB, ETC, and ETD are known so far [218].
However, ETA and ETB are implicated in human skin infections [219], while ETC and ETD are more
related to non-human hosts. Both, ETA and ETB cleave desmoglein 1, a glycoprotein responsible
for cell-cell adhesion of the keratinocytes in stratum granulosum without affecting E-cadherin [220].
In addition to serine proteases, S. aureus secretes six serine protease-like proteins (SplA-SplF) [221],
which show amino acid homology with SspA and ETs [222]. In contrast to other serine proteases, Spls
are mainly implicated in allergic airway reactions such as asthma [223].
Aureolysin (Aur) belongs to the family of zinc-dependent metallopeptidases [224]. In vitro,
it was shown that Aur cleaves α1-protease inhibitor, which is responsible for regulation of neutrophil
elastase [225]. In line with this, Burlak and colleagues demostrated that Aur is expressed within
phagocytic vacuoles of human neutrophils [226]. Moreover, Aur can cleave the antimicrobial peptide
LL-37 [227] and complement component C3 to C3b [228]. As a result, S. aureus is poorly opsonized
leading to attenuated phagocytosis and bacterial killing [228].
Staphylokinase (SAK) is a secreted and cell surface associated virulence factor of staphylococci and
is structurally unrelated to streptokinase [229]. Especially clinical S. aureus isolates of skin and mucosal
origin express high levels of SAK [230]. SAK stimulates the production of human antimicrobial peptides
(LL-37 and α-defensins), binds, and inactivates their bactericidal properties [231,232]. However,
the main SAK activity affects its ability to convert plasminogen to an active proteolytic enzyme
plasmin [230]. First, S. aureus binds plasminogen via surface expressed proteins (e.g., FnBPA and
FnBPB) and second, SAK activates plasminogen to plasmin, thereby creating a bacteria-bound serine
protease activity [233]. These events enable the bacteria to degrade immunoglobulin G (IgG) and C3b,
thereby contributing to immune evasion [234].
5.3. Two Component Systems and Exotoxin Regulation
During bacterial infections the regulation of exotoxins is mediated by a complex network which
incorporates environmental signals towards coordinated responses against host microenvironment.
Two component systems (TCS) are one such mechanism adopted by bacteria. An external signal
activates the membrane bound histidine kinase. This induces auto-phosphorylation and downstream
activation of a response regulator by its phosphorylation. The binding of the regulator to specific DNA
sequence results in its gene expression. Most important and well-studied TCS are AgrAC and SaeRS in
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S. aureus and CovR/S in GAS strains. Both are known to regulate the virulence factors that mitigate the
host responses during fulminant NSTIs [235,236].
Differential gene regulation of exotoxins by TCS determines the specificity of toxin gene expression
at the site of infection. S. aureus exotoxins are upregulated in a growth density dependent manner
during NSTIs [237,238]. Furthermore, leukocidins are found to be upregulated during NSTIs [239].
These virulence factors are mainly regulated by the intracellular effector responses belonging to agr
quorum-sensing system including the transcriptional regulators AgrA and RNA III [240–242]. The agr
system governs the expression of secreted virulence factors and exotoxins which enhance acute infection
and bacterial dissemination [240–242]. Virulence factor production is mainly regulated through two
pathways: (i) RNAIII-dependent synthesis of exotoxins and inhibition of cell surface factors and (ii) an
RNAIII-independent, AgrA-mediated production of PSMs and metabolic genes. However, mutations
in the agr-operon rendering dysfunctional Agr system are associated with adaptation of the bacteria to
host environment and inducing a more persistent phenotype [243]. Such Agr-defective systems are
usually detected in colonizing strains and in strains isolated from patients diagnosed with endocarditis
or bacteremia [244]. Similarly, a point mutation in the agrC region was associated with cytotoxic versus
colonizing properties of S. aureus phenotypic variants causing skin and soft tissue infections [245].
These data further support the importance of virulence regulation and its impact on clinical presentation.
Enhanced virulence expression mediated by active Agr system is usually detected during severe
invasive and acute infections such as NSTIs [246], whereas agr-mutants are usually implicated in
causing dormant state and chronic infections, such as endocarditis and osteomyelitis [240]. In addition
to the Agr system, the S. aureus exoprotein expression system (SaeRS) plays also an important role in
regulating virulence factor production at the tissue site. SaeRS consists of the histidine kinase SaeS
and the response regulator SaeR. SaeR activates transcription of the downstream target genes [247].
The activated SaeRS TCS induces the expression of several virulence factors, including α-toxin, β- and
γ-hemolysins, PVL, TSST-1, and exfoliative toxins [248,249]. Human neutrophil peptides 1, 2, and 3
(HNP1-3), which are located in azurophilic granules of neutrophils and calprotectin, a cytoplasmic
neutrophil peptide, activate the SaeRS system [250]. Therefore, neutrophil-mediated activation may
play a pivotal role in exotoxin regulation and toxin production at the tissue site. It was proposed
that SaeRS TCS acts downstream of Agr in virulence regulation and toxin production pathways [251].
However, the exact mechanism of a relationship between Agr and SaeRS systems is still not fully
understood. Moreover, recent studies have implicated that the Agr and SaeRS are independent systems
of toxin regulation [247,252,253].
Recent evidence indicates that GAS invasiveness is instigated by spontaneous mutations of the
CovR/S TCS [61,72,73,254]. CovR/S is a negative transcriptional regulator of around 15% of the GAS
genome. It was shown that mice tissue passage of GAS selects for a 7-bp frame-shift mutation in the
covS gene encoding the sensor kinase component and this in turn promotes GAS invasiveness [61,72,73].
Since that discovery several investigators reported the role of CovR/S system in severe invasive
infections. Mutations in that particular region result in the upregulation of several secreted virulence
factors, including a bacteriophage-encoded DNase [73], SLO [71], and SpyCEP [73]. In addition,
dysfunctionality of CovR/S results in loss of SpeB expression. Whether the loss of SpeB and/or enhanced
expression of other secreted virulence factors are beneficial for the bacteria or not, was discussed earlier
in this article. However, the role of the host tissue micro-environment and the availability of nutrients,
which influence the expression of response regulators during NSTIs is still not fully understood.
Future studies focused towards understanding the interplay between the signaling pathways will be
essential to better understand the physiological significance of toxin expression in the context of host
tissue micro-environment during NSTIs.
6. Treatment
The management of NSTI patients includes fluid resuscitation, support of failing organs, rapid
surgical debridement of infected tissue, broad spectrum antibiotics, and adjuvant intravenous
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polyspecific immunoglobulin G (IVIG) and/or hyperbaric oxygen (HBO) therapy [1,2,255–257].
Aggressive tissue debridement guarantees elimination of the necrotic tissue and the source of infection
and exotoxins. Recent studies suggest that early surgical intervention within 24 h post admission
significantly improves the survival of patients [258,259]. Survival further increases if debridement is
performed even earlier [260,261].
Nearly all GAS are susceptible to penicillin. However, the high bacterial load in the tissue results in
most GAS being in the stationary or in biofilm stage, making cell-wall active antimicrobials not always
effective [61,262]. Therefore, treatment with clindamycin, a protein synthesis inhibitor, in combination
with penicillin is strongly recommended [257]. However, clinical data based on randomized trials are
lacking. Clindamycin inhibits production of SAgs [263] and a recent observational study showed that
clindamycin improves survival of patients with STSS [264]. Nonetheless, experimental data suggest
that sub-inhibitory concentrations of clindamycin enhance expression and activity of SLO in vitro,
but suppress the expression of SpeB [265,266]. In addition, the rise of clindamycin resistant GAS
strains [267] raises concerns about the benefits of clindamycin treatment.
When MRSA is suspected, i.v. linezolid or daptomycin may be added in preference of vancomycin,
as the latter has no effect on exotoxin production [1,257]. In addition, poor tissue penetration of
vancomycin lowers its efficacy in severe NSTIs [268]. Linezolid, an oxazolidinone, inhibits bacterial
exotoxin production [269] and several studies concluded that linezolid is an effective alternative to
vancomycin for treatment of skin infections caused by MRSA [270–272]. In contrast, daptomycin
is a cyclic lipopeptide with a distinct mechanism of action. It inserts into the cell membrane of
bacteria via phosphatidylglycerol and disrupts membrane integrity by extracting lipids resulting in
ion leakage [273]. Overall, inhibitors of toxin production, such as clindamycin, linezolid or rifampicin
are commonly recommended for inclusion in antimicrobial treatment of necrotizing infections.
The use of IVIG and HBO as adjunctive therapies is still under debate. Experimental data showed
that IVIG neutralizes bacterial exotoxins, including streptococcal and staphylococcal SAgs [274–277],
α-toxin [145], bi-component leukocidins [145], and SLO [278] among others. However, clinical studies
contradict each other. One of the first studies in seven patients with severe NSTI caused by GAS
suggested a beneficial role of IVIG [279]. A prospective observational study conducted in STSS patients
showed reduced mortality in patients receiving IVIG, while a sub-analysis of the NSTI patients did
not confirm this observation [264]. In line with this, a recent placebo-controlled clinical trial called
INSTINCT, showed no benefit of the IVIG use in NSTIs [255]. The latest systematic review and
meta-analysis of the previous single randomized and four nonrandomized studies revealed that
administration of IVIG to clindamycin treated patients is associated with a significant reduction
in mortality [280]. Same contradiction applies to adjunctive HBO treatment. Two recent studies
concluded that HBO treatment is associated with significant reduction in mortality in NSTIs [7,281].
Nevertheless, a systematic literature review of 57 studies revealed that HBO is not useful for the
treatment of NSTIs [282]. Currently, a study delineating the effects of HBO on biomarkers in NSTIs is
being performed in Denmark [283].
7. Conclusions
NSTIs are rapidly progressing, life-threatening necrotic infections of any layer of the soft tissue
compartment. The underlying mechanisms of these infections are poorly understood. GAS and
S. aureus are equipped with an arsenal of virulence factors that contribute to disease pathogenesis.
In NSTIs, there is a clear correlation between exotoxin production at the site of infection and tissue
pathology and systemic toxicity. Therefore, secreted virulence factors, including SAgs, pore-forming
toxins, and immunomodulatory proteases, are attractive targets for therapeutic approaches. However,
further understanding of mechanistic actions of the exotoxins in vivo and in vitro is needed.
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